Literature DB >> 16151893

Behavioural factors related to metabolic control in patients with phenylketonuria.

M R Crone1, F J van Spronsen, K Oudshoorn, J Bekhof, G van Rijn, P H Verkerk.   

Abstract

BACKGROUND: The objective of this study was to determine the importance of parental factors possibly related to dietary control in early and continuously treated patients with phenylketonuria (PKU).
METHODS: A questionnaire was disseminated among parents of 238 patients with PKU born after the nationwide introduction of newborn screening for PKU (1 September 1974) until 31 December 1995. The questionnaire was based on a behavioural model measuring people's attitudes, subjective norms, and self-efficacy. Dietary control was defined on the basis of mean phenylalanine (Phe) concentration of the PKU patients measured between 1 January 1994 and 31 December 1996.
RESULTS: Response rate was 71%. Attitudes: children of parents who believed that their child adheres well to the diet, even if his or her Phe concentrations are sometimes too high, had lower Phe concentrations than children of parents who disagree with this statement (adjusted difference -103 micromol/L, p < 0.001). Subjective norm: Phe concentrations were higher when parents answered that their relatives did not approve when their child deviates from the diet (p = 0.004). Self-efficacy: children of parents who reported difficulties in having their child eat the synthetic protein substitute three times a day had higher Phe concentrations than those of parents who did not have such difficulties (adjusted difference 156 micromol/L, p = 0.007).
CONCLUSION: More attention should be given to parents having their child eat the synthetic protein substitute at least three times a day and to teaching parents to keep strictly to the diet without being too rigid. These factors were strongly associated to dietary control and may be amenable to change.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16151893     DOI: 10.1007/s10545-005-0014-0

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  21 in total

1.  Influence of knowledge of the disease on metabolic control in phenylketonuria.

Authors:  Jolita Bekhof; Francjan J van Spronsen; Matty R Crone; Margreet van Rijn; Carin G M Oudshoorn; Paul H Verkerk
Journal:  Eur J Pediatr       Date:  2003-04-08       Impact factor: 3.183

Review 2.  Adolescent adherence in type 1 diabetes.

Authors:  Robert P Hoffman
Journal:  Compr Ther       Date:  2002

3.  Treatment products and approaches for phenylketonuria: improved palatability and flexibility demonstrate safety, efficacy and acceptance in US clinical trials.

Authors:  A P Prince; M P McMurray; N R Buist
Journal:  J Inherit Metab Dis       Date:  1997-08       Impact factor: 4.982

4.  Does a single plasma phenylalanine predict quality of control in phenylketonuria?

Authors:  A MacDonald; G W Rylance; D Asplin; S K Hall; I W Booth
Journal:  Arch Dis Child       Date:  1998-02       Impact factor: 3.791

5.  Factors affecting the variation in plasma phenylalanine in patients with phenylketonuria on diet.

Authors:  A MacDonald; G Rylance; S K Hall; D Asplin; I W Booth
Journal:  Arch Dis Child       Date:  1996-05       Impact factor: 3.791

6.  Behaviour and school achievement in patients with early and continuously treated phenylketonuria.

Authors:  B A Stemerdink; A F Kalverboer; J J van der Meere; M W van der Molen; J Huisman; L W de Jong; F M Slijper; P H Verkerk; F J van Spronsen
Journal:  J Inherit Metab Dis       Date:  2000-09       Impact factor: 4.982

7.  Blood phenylalanine control in adolescents with phenylketonuria.

Authors:  John H Walter; Fiona J White
Journal:  Int J Adolesc Med Health       Date:  2004 Jan-Mar

8.  Psychological and social findings in adolescents with phenylketonuria.

Authors:  J Weglage; B Fünders; B Wilken; D Schubert; E Schmidt; P Burgard; K Ullrich
Journal:  Eur J Pediatr       Date:  1992-07       Impact factor: 3.183

9.  Predictors of mean phenylalanine levels during the first five years of life in patients with phenylketonuria who were treated early. Dutch National PKU Steering Committee.

Authors:  P H Verkerk; F J van Spronsen; M van Houten; G P Smit; R C Sengers
Journal:  Acta Paediatr Suppl       Date:  1994-12

10.  Plasma phenylalanine and tyrosine responses to different nutritional conditions (fasting/postprandial) in patients with phenylketonuria: effect of sample timing.

Authors:  F J van Spronsen; M van Rijn; T van Dijk; G P Smit; D J Reijngoud; R Berger; H S Heymans
Journal:  Pediatrics       Date:  1993-10       Impact factor: 7.124

View more
  25 in total

1.  Outcomes of phenylketonuria with relevance to follow-up.

Authors:  F J van Spronsen; A Bélanger-Quintana
Journal:  JIMD Rep       Date:  2011-06-22

2.  Demographic and Psychosocial Influences on Treatment Adherence for Children and Adolescents with PKU: A Systematic Review.

Authors:  Emma Medford; Dougal Julian Hare; Anja Wittkowski
Journal:  JIMD Rep       Date:  2017-08-25

3.  Predictability and inconsistencies in the cognitive outcome of early treated PKU patients.

Authors:  Filippo Manti; Francesca Nardecchia; Sabrina Paci; Flavia Chiarotti; Claudia Carducci; Carla Carducci; Silvia Dalmazzone; Graziella Cefalo; Elisabetta Salvatici; Giuseppe Banderali; Vincenzo Leuzzi
Journal:  J Inherit Metab Dis       Date:  2017-08-23       Impact factor: 4.982

Review 4.  The reality of dietary compliance in the management of phenylketonuria.

Authors:  Anita MacDonald; Hulya Gokmen-Ozel; Margreet van Rijn; Peter Burgard
Journal:  J Inherit Metab Dis       Date:  2010-04-07       Impact factor: 4.982

5.  Family conditions and dietary control in phenylketonuria.

Authors:  G M Olsson; S M Montgomery; J Alm
Journal:  J Inherit Metab Dis       Date:  2007-06-14       Impact factor: 4.982

Review 6.  Large neutral amino acids in the treatment of PKU: from theory to practice.

Authors:  Francjan J van Spronsen; Martijn J de Groot; Marieke Hoeksma; Dirk-Jan Reijngoud; Margreet van Rijn
Journal:  J Inherit Metab Dis       Date:  2010-10-26       Impact factor: 4.982

Review 7.  The truth of treating patients with phenylketonuria after childhood: the need for a new guideline.

Authors:  F J van Spronsen; P Burgard
Journal:  J Inherit Metab Dis       Date:  2008-08-12       Impact factor: 4.982

8.  Phenylalanine tolerance can already reliably be assessed at the age of 2 years in patients with PKU.

Authors:  F J van Spronsen; M van Rijn; B Dorgelo; M Hoeksma; A M Bosch; M F Mulder; J B C de Klerk; T de Koning; M Estela Rubio-Gozalbo; M de Vries; P H Verkerk
Journal:  J Inherit Metab Dis       Date:  2009-01-10       Impact factor: 4.982

9.  Reassessment of phenylalanine tolerance in adults with phenylketonuria is needed as body mass changes.

Authors:  Erin L MacLeod; Sally T Gleason; Sandra C van Calcar; Denise M Ney
Journal:  Mol Genet Metab       Date:  2009-08-08       Impact factor: 4.797

Review 10.  The complete European guidelines on phenylketonuria: diagnosis and treatment.

Authors:  A M J van Wegberg; A MacDonald; K Ahring; A Bélanger-Quintana; N Blau; A M Bosch; A Burlina; J Campistol; F Feillet; M Giżewska; S C Huijbregts; S Kearney; V Leuzzi; F Maillot; A C Muntau; M van Rijn; F Trefz; J H Walter; F J van Spronsen
Journal:  Orphanet J Rare Dis       Date:  2017-10-12       Impact factor: 4.123

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.